Resources
About Us
Home Report
Store
Continuous Bioprocessing Market
Continuous Bioprocessing Market by Product (Filtration, Chromatography, Bioreactor, Incubator, Centrifuge, Reagents) Process (Upstream, Downstream) Application (Monoclonal Antibodies, Vaccines, Plasma Fractionation, R&D) End User - Global Forecast to 2031
Report ID:MRHC - 104380 Pages: 220 Mar-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursThe Continuous Bioprocessing Market was valued at $0.33 billion in 2023. This market is expected to reach $1.32 billion by 2031, from an estimated $0.38 billion in 2024, at a CAGR of 19.6% during the forecast period 2024-2031.
Continuous Bioprocessing Market Size & Forecast
Continuous bioprocessing consists of integrated continuous unit processes without intermediate holding tanks through which product travels into containers in a constant flow. Continuous unit operations are characterized by extremely intensified processing with short downtimes. An end-to-end bioprocess involves a perfusion bioreactor, multi-column chromatography systems, and multi-column intermediate purification. Some pharmaceutical and biopharmaceutical manufacturers adopt a hybrid approach for continuous biopharmaceutical manufacturing in which only the upstream or downstream process is continuous.
The growth of the continuous bioprocessing market is driven by the rising demand for biopharmaceuticals, the emergence of continuous end-to-end bioprocessing, global initiatives supporting the adoption of biopharmaceuticals, and the advantages of continuous manufacturing over fed-batch processes. However, high capital investment requirements and operational complexities in continuous bioprocessing restrain the growth of this market.
Furthermore, Bioprocessing 4.0 and the increasing use of continuous bioprocessing for monoclonal antibody production are expected to generate growth opportunities for the stakeholders in this market. However, cross-contamination risks and process development control are major challenges impacting market growth.
Rising Demand for Biopharmaceuticals
The demand for biopharmaceuticals is rising due to their ability to target specific molecules, their lower side effects, and their high activity and specificity. Biopharmaceuticals are increasingly being used for treating Immune-mediated Inflammatory Diseases (IMIDs), including Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), and cancer. The gradual increase in approvals for biopharmaceuticals also supports the growth of this market. According to the U.S. FDA, out of the total drugs approved in 2022, 15 were biologics, compared to 13 in 2020.
The implementation of continuous manufacturing processes in commercial manufacturing improves productivity and decreases manufacturing costs, reducing the prices of biopharmaceutical products, making medicines more accessible, and improving the quality of care. Continuous bioprocessing is transforming biopharmaceutical manufacturing. The benefits of continuous flow manufacturing, such as increased process design flexibility, improved process economics, easy scale-up, and short development times, are boosting the adoption of continuous bioprocessing in biopharmaceutical production.
Furthermore, government initiatives supporting the adoption of biopharmaceuticals are driving the continuous bioprocessing market. For instance, in September 2022, the U.S. government announced an investment of $2 billion in a biomanufacturing initiative aimed at expanding and improving the domestic biopharmaceutical manufacturing capacity. Also, in August 2023, the U.K. government invested $16.3 million (€15 million) in the country’s biopharmaceutical manufacturing industry via its national innovation agency. The investment was aimed at supporting the country's life sciences sector.
Advantages of Continuous Manufacturing Over Batch Manufacturing
Continuous manufacturing is a new trend in the manufacturing industry. Industries are adopting continuous manufacturing to improve efficiencies and increase profits. Although batch manufacturing is currently the most preferred manufacturing method, continuous biomanufacturing is being increasingly accepted in the pharmaceutical industry due to the commercial advantages it offers over batch manufacturing. Some of the advantages of continuous-flow manufacturing are as follows:
- Continuous bioprocessing facilities are at least 70% smaller compared to batch production facilities. This size reduction reduces operating costs.
- In continuous bioprocessing, the same equipment used during process development is utilized for production, which eliminates validation issues and reduces costs.
- The integration of measuring equipment and real-time sensors with continuous manufacturing equipment enables feedback control and continuous process monitoring. The continuous generation of process data allows manufacturers to improve processes through data analysis. Real-time process control not only improves product quality but also enhances productivity (following the U.S. FDA’s Quality-by-Design (QbD) approach to manufacturing).
- Over the last few years, pharmaceutical recalls have increased exponentially due to inferior drug quality and poor drug production practices. Pharmaceutical manufacturers are now considering continuous manufacturing to be the go-to strategy.
- With continuous bioprocessing, manufacturers can quickly adapt to market changes and eliminate drug shortages.
Click here to: Get Free Sample Pages of this Report
Key Findings in the Continuous Bioprocessing Market Study:
Filtration Systems & Consumables Expected to Account for the Largest Market Share in 2024
Based on product, the continuous bioprocessing market is segmented into filtration systems & consumables, chromatography systems & consumables, bioreactors, sterilizers, centrifuges, incubators & shakers; cell culture media, buffers, and reagents; and other instruments & consumables. In 2024, the filtration systems & consumables segment is expected to account for the largest share of the continuous bioprocessing market. The segment’s large market share is attributed to the high reliance on filtration systems in bioprocessing separation techniques, the reusability of filters across every step in bioprocessing, and the need for high cell densities in controlling the bioburden in biopharmaceuticals. Key market players are focused on developing technologically advanced filtration systems to cater to the growing demand. For instance, in November 2022, High Purity New England (U.S.) launched the OptiMaxx Tangential Flow Filtration (TFF) system. The filtration system offers simplicity of use for biomanufacturing and is customizable.
Downstream Processes Expected to Dominate the Continuous Bioprocessing Market in 2024
Based on process type, the continuous bioprocessing market is segmented into upstream processes and downstream processes. In 2024, the downstream processes segment is expected to account for the larger share of the continuous bioprocessing market. Downstream processing is an integral part and the largest process segment in continuous bioprocessing. Additionally, advancements in downstream processing, such as the introduction of multi-column chromatography and single-pass tangential flow filtration, support the segment’s large market share. Further, ultra-scale-down bioprocessing is a recent trend in downstream processing for rapid process development and optimization in biopharmaceutical manufacturing.
The R&D Applications Segment Projected to Register the Higher CAGR During the Forecast Period
Based on application, the continuous bioprocessing market is segmented into commercial applications and R&D applications. The R&D applications segment is expected to register the higher CAGR during the forecast period. The high growth of this segment is driven by the increasing clinical studies for monoclonal antibodies, gene therapies, and vaccines. The increasing importance of biopharmaceuticals (including monoclonal antibodies) and the growing focus on R&D to develop vaccines and therapies are driving the growth of this segment. For instance, in March 2023, the U.S. government invested $31.9 billion in mRNA vaccine research and procurement.
Pharmaceutical & Biotechnology Companies Expected to Account for the Largest Market Share in 2024
Based on end user, the continuous bioprocessing market is segmented into pharmaceutical & biotechnology companies, CDMOs & CROs, and academic & research institutes. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the continuous bioprocessing market. The segment’s large market share is attributed to the need to develop new therapies owing to increasing disease prevalence and the increased spending on pharmaceutical R&D. For instance, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), global pharmaceutical R&D expenditure is expected to reach $213 billion in 2026 from $179 billion in 2020. Additionally, pharma and biopharma manufacturers' shift from batch to continuous processing and regulatory authorities’ growing focus on continuous bioprocessing are also contributing to the segment’s large market share.
North America to be the Largest Regional Market in 2024
In 2024, North America is expected to account for the largest share of the continuous bioprocessing market. North America's large market share is attributed to the region’s well-established manufacturing base focused on innovating production processes, the rising demand for biopharmaceuticals, government support for the adoption of continuous bioprocessing, and the presence of large biopharmaceutical manufacturers. In February 2020, the U.S. FDA transitioned to a new regulatory pathway to allow biopharmaceutical manufacturers to seek the FDA’s approval for biosimilars to bring them to the market. Additionally, the FDA has approved several drug products manufactured through continuous processes. For instance, at the start of 2022, the FDA approved six finished solid oral drugs produced through continuous manufacturing.
Continuous Bioprocessing Market: Competitive Analysis
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the last 3–4 years (2020–2024). The key players operating in the continuous bioprocessing market include 3M Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Eppendorf AG (Germany), Danaher Corporation (U.S.), Merck KGaA (Germany), Repligen Corporation (U.S.), Getinge AB (Sweden), Bionet (Spain), Corning Incorporated (U.S.), Fujifilm Holdings Corporation (Japan), Entegris, Inc. (U.S.), and Meissner Corporation (U.S.).
Continuous Bioprocessing Market Report Summary:
|
Particulars |
Details |
|
Number of Pages |
~220 |
|
Format |
|
|
Forecast Period |
2024–2031 |
|
Base Year |
2023 |
|
CAGR |
19.6% |
|
Estimated Market Size (Value) |
$1.32 Billion by 2031 |
|
Segments Covered |
By Product
By Process Type
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, and RoE), Asia-Pacific (China, Japan, India, South Korea, and RoAPAC), Latin America, and the Middle East & Africa |
|
Key Companies Profiled |
3M Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Eppendorf AG (Germany), Danaher Corporation (U.S.), Merck KGaA (Germany), Repligen Corporation (U.S.), Getinge AB (Sweden), Bionet (Spain), Corning Incorporated (U.S.), Fujifilm Holdings Corporation (Japan), Entegris, Inc. (U.S.), and Meissner Corporation (U.S.) |
Key questions answered in the report:
The continuous bioprocessing market study covers products, processes, applications, and end users in the continuous bioprocessing market. This report analyzes various segments of the continuous bioprocessing market at the regional and country levels.
The continuous bioprocessing market is projected to reach $1.32 billion by 2031 at a CAGR of 19.6% from 2024 to 2031.
In 2024, the filtration systems & consumables segment is expected to account for the largest share of the continuous bioprocessing market, mainly due to the growing preference for filtration systems in bioprocessing separation techniques, the reusability of filters across every step in bioprocessing, and the need for high cell densities in controlling the bioburden in biopharmaceuticals.
In 2024, the commercial applications segment is expected to account for the major share of the continuous bioprocessing market, mainly due to increasing investments in constructing facilities compatible with continuous bioprocessing for the commercial manufacture of biopharmaceuticals.
The growth of this market is driven by the rising demand for biopharmaceuticals, the emergence of continuous end-to-end bioprocessing, global initiatives supporting the adoption of biopharmaceuticals, and the advantages of continuous bioprocessing over batch manufacturing.
Furthermore, Bioprocessing 4.0 and the increasing use of continuous bioprocessing for MAB production are expected to offer growth opportunities for the players in this market.
The key players operating in the continuous bioprocessing market are 3M Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Eppendorf AG (Germany), Danaher Corporation (U.S.), Merck KGaA (Germany), Repligen Corporation (U.S.), Getinge AB (Sweden), Bionet (Spain), Corning Incorporated (U.S.), Fujifilm Holdings Corporation (Japan), Entegris, Inc. (U.S.), and Meissner Corporation (U.S.).
Emerging countries in Asia-Pacific are expected to offer significant growth opportunities for the vendors in this market due to the evolving landscape of biopharmaceuticals in Asian countries. China and India are among the leading countries in the development and commercialization of biosimilars. The Chinese government has undertaken several initiatives to promote the development and adoption of biosimilars. The development of multinational clinical centers, Accelerated approvals for special medicines, and global sharing of clinical data are some of the initiatives driving the adoption of biosimilars in China.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Data Collection and Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Rising Demand for Biopharmaceuticals
4.2.2. Emergence of Continuous End-to-end Bioprocessing
4.2.3. Global Initiatives Supporting the Adoption of Biopharmaceuticals
4.2.4. Advantages of Continuous Bioprocessing over Batch Manufacturing
4.3. Restraints
4.3.1. High Capital Investment Requirements
4.3.2. Operational Complexities in Continuous Bioprocessing
4.4. Opportunities
4.4.1. Shift Toward Bioprocessing 4.0
4.4.2. Increasing Use of Continuous Bioprocessing for Monoclonal Antibody Production
4.5. Challenges
4.5.1. Risk of Cross Contamination
4.5.2. Process Development Control
4.5.3. Manufacturers’ Reluctance to Shift from Batch Manufacturing to Continuous Manufacturing
4.6. Factor Analysis
4.7. Key Trends
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Porter’s Five Forces Analysis
5. Continuous Bioprocessing Market Assessment—by Product
5.1. Overview
5.2. Filtration Systems & Consumables
5.3. Chromatography Systems & Consumables
5.4. Cell Culture Media, Buffers, and Reagents
5.5. Incubators & Shakers
5.6. Bioreactors
5.7. Centrifuges
5.8. Sterilizers
5.9. Other Instruments & Consumables
6. Continuous Bioprocessing Market Assessment—by Process Type
6.1. Overview
6.2. Upstream Processes
6.3. Downstream Processes
7. Continuous Bioprocessing Market Assessment—by Application
7.1. Overview
7.2. Commercial Applications
7.2.1. Monoclonal Antibodies (mAb) Production
7.2.2. Cell & Gene Therapy Production
7.2.3. Vaccine Manufacturing
7.2.4. Plasma Fractionation
7.2.5. Recombinant Protein Production
7.3. Research & Development (R&D) Applications
8. Continuous Bioprocessing Market Assessment—by End User
8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Contract Development & Manufacturing Organizations (CDMOs) & Contract Research Organizations (CROs)
8.4. Academic & Research Institutes
9. Continuous Bioprocessing Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Switzerland
9.3.7. Ireland
9.3.8. Denmark
9.3.9. Belgium
9.3.10. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. South Korea
9.4.5. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis/Market Rankings of Key Players (2023)
11. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)
11.1. 3M Company
11.2. Thermo Fisher Scientific, Inc.
11.3. Sartorius AG
11.4. Eppendorf AG
11.5. Danaher Corporation
11.6. Merck KGaA
11.7. Repligen Corporation
11.8. Getinge AB
11.9. Bionet
11.10. Corning Incorporated
11.11. Fujifilm Holdings Corporation
11.12. Entegris, Inc.
11.13. Meissner Corporation
(Note: SWOT analyses will be provided for the top 5 companies.)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Global Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 2 Global Filtration Systems & Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Global Chromatography Systems & Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Cell Culture Media, Buffers, and Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Global Incubators & Shakers Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Bioreactors Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Centrifuges Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Global Sterilizers Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Global Other Instruments & Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 11 Global Upstream Processes Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Downstream Processes Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 14 Global Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 15 Global Continuous Bioprocessing Market for Commercial Applications, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Continuous Bioprocessing Market for Monoclonal Antibodies Production, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Continuous Bioprocessing Market for Cell & Gene Therapy Production, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Continuous Bioprocessing Market for Vaccine Manufacturing, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Continuous Bioprocessing Market for Plasma Fractionation, by Country/Region, 2022–2031 (USD Million)
Table 20 Global Continuous Bioprocessing Market for Recombinant Protein Production, by Country/Region, 2022–2031 (USD Million)
Table 21 Global Continuous Bioprocessing Market for R&D Applications, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 23 Global Continuous Bioprocessing Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Continuous Bioprocessing Market for CDMOs & CROs, by Country/Region, 2022–2031 (USD Million)
Table 25 Global Continuous Bioprocessing Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Continuous Bioprocessing Market, by Region, 2022–2031 (USD Million)
Table 27 North America: Continuous Bioprocessing Market, by Country, 2022–2031 (USD Million)
Table 28 North America: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 29 North America: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 30 North America: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 31 North America: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 32 North America: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 33 U.S.: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 34 U.S.: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 35 U.S.: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 36 U.S.: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 37 U.S.: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 38 Canada: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 39 Canada: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 40 Canada: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 41 Canada: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 42 Canada: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 43 Europe: Continuous Bioprocessing Market, by Country/Region, 2022–2031 (USD Million)
Table 44 Europe: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 45 Europe: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 46 Europe: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 47 Europe: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 48 Europe: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 49 Germany: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 50 Germany: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 51 Germany: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 52 Germany: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 53 Germany: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 54 France: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 55 France: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 56 France: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 57 France: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 58 France: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 59 U.K.: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 60 U.K.: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 61 U.K.: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 62 U.K.: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 63 U.K.: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 64 Italy: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 65 Italy: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 66 Italy: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 67 Italy: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 68 Italy: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 69 Spain: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 70 Spain: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 71 Spain: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 72 Spain: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 73 Spain: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 74 Switzerland: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 75 Switzerland: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 76 Switzerland: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 77 Switzerland: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 78 Switzerland: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 79 Ireland: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 80 Ireland: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 81 Ireland: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 82 Ireland: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 83 Ireland: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 84 Denmark: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 85 Denmark: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 86 Denmark: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 87 Denmark: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 88 Denmark: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 89 Belgium: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 90 Belgium: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 91 Belgium: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 92 Belgium: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 93 Belgium: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 94 Rest of Europe: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 95 Rest of Europe: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 96 Rest of Europe: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 97 Rest of Europe: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 98 Rest of Europe: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 99 Asia-Pacific: Continuous Bioprocessing Market, by Country/Region, 2022–2031 (USD Million)
Table 100 Asia-Pacific: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 101 Asia-Pacific: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 102 Asia-Pacific: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 103 Asia-Pacific: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 104 Asia-Pacific: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 105 China: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 106 China: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 107 China: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 108 China: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 109 China: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 110 Japan: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 111 Japan: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 112 Japan: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 113 Japan: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 114 Japan: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 115 India: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 116 India: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 117 India: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 118 India: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 119 India: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 120 South Korea: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 121 South Korea: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 122 South Korea: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 123 South Korea: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 124 South Korea: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 125 Rest of Asia-Pacific: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 126 Rest of Asia-Pacific: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 127 Rest of Asia-Pacific: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 128 Rest of Asia-Pacific: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 129 Rest of Asia-Pacific: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 130 Latin America: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 131 Latin America: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 132 Latin America: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 133 Latin America: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 134 Latin America: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 135 Middle East & Africa: Continuous Bioprocessing Market, by Product, 2022–2031 (USD Million)
Table 136 Middle East & Africa: Continuous Bioprocessing Market, by Process Type, 2022–2031 (USD Million)
Table 137 Middle East & Africa: Continuous Bioprocessing Market, by Application, 2022–2031 (USD Million)
Table 138 Middle East & Africa: Continuous Bioprocessing Market for Commercial Applications, by Type, 2022–2031 (USD Million)
Table 139 Middle East & Africa: Continuous Bioprocessing Market, by End User, 2022–2031 (USD Million)
Table 140 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Continuous Bioprocessing Market, by Product, 2024 Vs. 2031 (USD Million)
Figure 8 Global Continuous Bioprocessing Market, by Process Type, 2024 Vs. 2031 (USD Million)
Figure 9 Global Continuous Bioprocessing Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 10 Global Continuous Bioprocessing Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 11 Global Continuous Bioprocessing Market, by Geography
Figure 12 Global Continuous Bioprocessing Market, by Product, 2024 Vs. 2031 (USD Million)
Figure 13 Global Continuous Bioprocessing Market, by Process Type, 2024 Vs. 2031 (USD Million)
Figure 14 Global Continuous Bioprocessing Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 15 Global Continuous Bioprocessing Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 16 Global Continuous Bioprocessing Market, by Geography, 2024 Vs. 2031 (USD Million)
Figure 17 North America: Continuous Bioprocessing Market Snapshot
Figure 18 Europe: Continuous Bioprocessing Market Snapshot
Figure 19 Asia-Pacific: Continuous Bioprocessing Market Snapshot
Figure 20 Key Growth Strategies Adopted by Leading Players, 2020–2024
Figure 21 Global Continuous Bioprocessing Market: Competitive Benchmarking, by Product
Figure 22 Global Continuous Bioprocessing Market: Competitive Dashboard
Figure 23 Global Continuous Bioprocessing Market: Market Share Analysis/Market Rankings (2023)
Figure 24 3M Company: Financial Snapshot (2023)
Figure 25 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Figure 26 Sartorius AG: Financial Snapshot (2023)
Figure 27 Eppendorf AG: Financial Snapshot (2022)
Figure 28 Danaher Corporation: Financial Snapshot (2023)
Figure 29 Merck KGaA: Financial Snapshot (2023)
Figure 30 Repligen Corporation: Financial Snapshot (2023)
Figure 31 Getinge AB: Financial Snapshot (2023)
Figure 32 Corning Incorporated: Financial Snapshot (2023)
Figure 33 Fujifilm Holdings Corporation: Financial Snapshot (2023)
Figure 34 Entegris, Inc.: Financial Snapshot (2023)
Figure 35 Fujifilm Holdings Corporation: Financial Snapshot (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Europe Continuous Bioprocessing Market - Opportunity Analysis And Industry Forecast (2024-2030)
Published Date: Jul-2024
Continuous Glucose Monitoring Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
